| Summary: | 碩士 === 國立交通大學 === 經營管理研究所 === 106 === This thesis applies the non-oriented slack-based model (SBM) in the data envelopment analysis (DEA) to compute disaggregate input and output efficiency scores of Taiwan's 38 listed and OTC pharmaceutical companies. The R&D expenses, marketing and management costs, and invested capital are the three inputs, and revenue and intangible assets are the two outputs. The data period is from 2012 to 2016. The major empirical results are: (1) In terms of inputs, there is much room for improvement in R&D expenses and capital efficiency, while marketing and management expenses relatively perform efficiently. In terms of outputs, most companies have much room for improvement in the efficiency of intangible assets while operating income relatively performs efficiently. (2) Most companies whose R&D expenses account for a large proportion of their invested capital do not have higher intangible assets efficiency, which should be improved. (3) R&D, invested capital, and revenue efficiencies of new drug companies are significantly lower than those of other pharmaceutical companies. However, the intangible assets efficiency of new drug companies are superior to other pharmaceutical companies.
|
|---|
